Crosley CRSH268MS2 Bedienungsanleitung PDF herunterladen (Seite 12)

xii

SUMMARY

Clostridium difficile was first recognized as a potential gastric acid resistant, spore producing

pathogen in 1978. Now it is regarded as a rapidly emerging antibiotic resistant pathogen that

causes disease in humans and animals. C. difficile infections are the result of a strong

bacterial toxin production and are often associated with previous consumption of

antibiotics. Broad-spectrum antibiotics kill a whole range of bacteria, which results in a

disruption of the normal intestine flora. In this way, C. difficile can predominate in het

intestine and hereby lead to different diseases like antibiotic-associated diarrhea and

pseudomembranous colitis.

In the last years, a worldwide increase in the number and the severity of C. difficile infections

was observed. In addition, a reduced effectiveness of antibiotics against C. difficile was

noted. Considering the huge costs for the management of C. difficile infections, estimated at

3 billion euro in the European Union each year, a better solution for the current antibiotic

treatment with metronidazole and vancomycin should be looked for. Antimicrobial

components that exhibit a narrow spectrum activity against C. difficile strains and leave

other non-pathogenic intestinal bacteria intact, are a potential solution.

Prior studies at the department of Pathology, Bacteriology and Poultry Diseases (Faculty of

Veterinary Medicine, Ghent University), already demonstrated the production of

antimicrobial components against C. difficile by a particular Bacillus amyloliquefaciens and

Clostridium perfringens. This project aims to characterize, purify and identify the

components responsible for this antimicrobial activity. Then, the selectivity of the

components against other non-pathogenic bacteria of the intestinal microflora is examined.

The presence of C. difficile toxin genes, responsible for the virulence of the strain, is also

studied in different C. difficile strains. If these compounds exhibit a strong antimicrobial

activity against C. difficile, are not cytotoxic and kill only few non-pathogenic intestinal

bacteria, they can potentially be used for the treatment of C. difficile infections.

1 2 ... 7 8 9 10 11 12 13 14 15 16 17 ... 89 90

Keine Kommentare

Crosley CRSH268MS2 Bedienungsanleitung Seite 12